Padcev – Health

New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes

Astellas and Seattle Genetics impressed Wall Street last fall when their combination of Padcev and Merck’s Keytruda fought off advanced bladder cancer in previously untreated patients. Friday, the partners presented updated results that look even better. They might even be good enough to snag an expedited regulatory review, analysts say—and at least one market-watcher hiked… Read More »

FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer Print this page TOKYO and BOTHELL, Wash., Dec. 18, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Padcev™ for the… Read More »